Esperion Therapeutics (ESPR) Boosted to Purchase by BidaskClub

Esperion Therapeutics (ESPR) Boosted  to Purchase by BidaskClub

BidaskClub upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a report published on Friday, October 19th.

Several other brokerages also recently commented on ESPR. Zacks Investment Research downgraded Esperion Therapeutics from a hold rating to a sell rating in a research note on Tuesday, July 10th. Northland Securities downgraded Esperion Therapeutics from an outperform rating to a market perform rating in a research note on Wednesday, July 11th. Stifel Nicolaus initiated coverage on Esperion Therapeutics in a research note on Friday, September 14th. They set a buy rating and a $89.00 target price for the company. BTIG Research initiated coverage on Esperion Therapeutics in a research note on Tuesday, October 16th. They set a buy rating and a $82.00 target price for the company. Finally, Chardan Capital upgraded Esperion Therapeutics to a hold rating and set a $32.50 price target for the company in a research note on Friday, July 20th. Two analysts have rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of Buy and an average price target of $75.96.

Shares of NASDAQ:ESPR traded up $3.23 during trading on Friday, hitting $59.11. 1,129,980 shares of the company were exchanged, compared to its average volume of 863,591. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -8.47 and a beta of 2.20. Esperion Therapeutics has a fifty-two week low of $33.06 and a fifty-two week high of $82.68.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.64) by ($0.22). During the same period in the prior year, the company posted ($1.86) earnings per share. As a group, equities research analysts forecast that Esperion Therapeutics will post -6.31 EPS for the current year.

In other news, Director Roger S. Newton sold 17,700 shares of the company’s stock in a transaction on Monday, August 27th. The stock was sold at an average price of $51.05, for a total transaction of $903,585.00. Following the completion of the sale, the director now directly owns 615,726 shares in the company, valued at approximately $31,432,812.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Boxer Capital, Llc sold 40,000 shares of the business’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $55.21, for a total value of $2,208,400.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 177,327 shares of company stock valued at $9,732,065. Corporate insiders own 14.50% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. American Century Companies Inc. raised its holdings in shares of Esperion Therapeutics by 82.6% during the 3rd quarter. American Century Companies Inc. now owns 52,544 shares of the biopharmaceutical company’s stock worth $2,331,000 after buying an additional 23,769 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Esperion Therapeutics by 598.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 12,422 shares of the biopharmaceutical company’s stock worth $551,000 after buying an additional 10,643 shares in the last quarter. Creative Planning raised its holdings in shares of Esperion Therapeutics by 42.0% during the 3rd quarter. Creative Planning now owns 7,562 shares of the biopharmaceutical company’s stock worth $336,000 after buying an additional 2,236 shares in the last quarter. United Services Automobile Association raised its holdings in shares of Esperion Therapeutics by 1,126.0% during the 2nd quarter. United Services Automobile Association now owns 41,561 shares of the biopharmaceutical company’s stock worth $1,629,000 after buying an additional 38,171 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Esperion Therapeutics by 1.8% during the 2nd quarter. Northern Trust Corp now owns 590,104 shares of the biopharmaceutical company’s stock worth $23,126,000 after buying an additional 10,702 shares in the last quarter.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Article: Discount Rate

Related posts

Leave a Comment